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Brain and thyroid tissue contain membrane-bound colchicine-binding activity that is not due to 
contamination by loosely bound cytoplasmic tubulin. This activity can be solubilized to the extent of 80 
to 90% by treatment with 0.2% Nonidet P-40 with retention of colchicine binding. Extracts so obtained 
contain a prominent protein band in disc gel electrophoresis that co-migrates with tubulin. 
Membranes, and the solubilized protein therefrom, exhibit ligand binding properties like tubulin; for 
colchicine the K, is -1 x lo6 Mm1 in brain and -0.6 x lo6 Mm’ in thyroid; for vinblastine the K, is -8 x 
lo6 M-’ for both tissues; and for podophyllot,oxin the K, is -2 x lo-’ M for both tissues. Displacement by 
analogues of colchicine is of the same order as for soluble tubulin. 
Although membrane-bound colchicine-binding activity shows greater thermal stability and a higher 
optimum binding temperature (54” uersus 37”) than soluble tubulin, this appears to be the result of the 
membrane environment since the solubilized binding activity behaves like the soluble tubulin. 
Antibody against soluble brain tubulin reacts with membranes and solubilized colchicine-binding 
activity from both brain and thyroid gland. 
We conclude that brain and thyroid membrane preparations contain firmly bound tubulin or a very 
similar protein. 
In recent years many studies have implicated the participa- 
tion of cytoplasmic microtubules in secretory phenomena (see 
Ref. 1 for review). The great bulk of this work has relied on the 
inhibitory effect on secretion of colchicine or vinblastine. These 
compounds disaggregate microtubules, bind to tubulin, the 
protomer of the microtubule, and interfere with in uitro 
polymerization of tubulin (2-5). They also cause readily visible 
structural changes in various cells. While colchicine can be a 
highly specific agent when used at low concentrations (l), both 
the requirement for low concentrations and the need to prove 
such specificity have frequently been disregarded and the 
interpretation of such studies may thus be open to doubt. Even 
when these precautions have been taken into account, it has 
been difficult to propose satisfactory models for the precise 
contribution and microtubule may make to the exo- or 
endocytosis of “packaged” material. 
In the thyroid gland low concentrations of colchicine block 
thyroglobulin endocytosis in an apparently specific manner (1). 
However, microtubules do not extend to the apical plasma 
membrane where the initial steps of this process occur (6,7). It 
has thus been difficult to explain satisfactorily the effect of 
colchicine on these early steps of secretion through the simple 
participation of cytoplasmic microtubules. 
Although soluble tubulin constitutes the bulk of the colchi- 
tine-binding activity of many tissues (8, 9), it has been shown 
that colchicine binding may also be associated with particulate 
cell fractions from several tissues (10-13). It has not been 
unequivocally established whether this binding activity is 
intrinsic to these particles or appears there during the course of 
preparation. We have, therefore, examined the possibility that 
colchicine may exert its effect on secretion by interacting with 
a membrane component rather than the cytoplasmic mi- 
crotubule. To this end we have compared colchicine binding 
protein in the plasma membranes of rat brain and beef thyroid 
with their cytoplasmic (microtubular) counterparts. The results 
suggest that a protein very similar to cytoplasmic tubulin is 
bound firmly to such membranes. 
EXPERIMENTAL PROCEDURES 
Methods 
Preparation of Membranes-Both rat brain (Sprague-Dawley fe- 
males) and beef thyroid membranes were isolated by a modification of 
the procedure of Wolff and Jones (14). In this method the tissue was 
briefly homogenized in a Polytron device and subsequently by eight 
strokes with a loose fitting Dounce homogenizer. The homogenate was 
centrifuged for 10 min at 200 x g to remove debris, and the resulting 
supernatant solution was centrifuged at 37,000 x g for 10 min. The 
resulting pellet was resuspended and washed twice with the homoge- 
nizing media (containing 0.25 M sucrose, 1 mM dithiothreitol, and 3 mM 
Tris-HCl buffer, pH 7.4) and centrifuged at 37,000 x g for 10 min. The 
upper, nearly white, portion of the pellet so obtained was removed 
without disturbing the lower pellet and resuspended in the same media 
and layered on a discontinuous sucrose gradient with layers of 30, 40, 
and 45% sucrose. Centrifugation was carried out with the SW 27 rotor 
at 27,000 rpm for 180 min or the SW 41 rotor at 41,000 rpm for 120 min. 
Bands at the interfaces were withdrawn from the top by syringe, 
diluted with water, and centrifuged for 15 min at 37,000 x g. Each 
pellet was divided into two portions: one was resuspended in the 
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homogenizing media for the adenylate cyclase assay; the other was 
dispersed in 0.25 M sucrose, 10 mM magnesium chloride, 10 mM phos- 
phate buffer (pH 6.5), and 0.1 mM GTP for the colchicine binding 
assay. 
In the early stage of our investigation we followed the particle 
fractionation procedure to Gray and Whittaker (15) with slight modifi- 
cation. The modification involved the mild (3 s) sonication of the crude 
mitochondrial fraction and three final washings with 0.32 M sucrose to 
ensure complete removal of trapped soluble colchicine-binding protein 
before putting the sample on the gradient. This procedure did not give 
a clear-cut separation of colchine-binding activity, possibly because 
sonication of the crude fraction disrupted the synaptosomes, yielding 
synaptosome fragments and ghosts as well as membranes (10). 
Therefore, most of our experiments were carried out with the mem- 
branes prepared by the first method. 
Assay of Colchicine-binding Actiuity-Bound [SH]colchi&e in 
both soluble and particulate fractions was determined by using the 
DEAE-impregnated filter paper technique of Weisenberg et al. (16) 
modified by Williams and Wolff (17). For membrane fractions this 
DEAE-filter paper method was verified by an alternate, discontinuous 
gradient method of Moore and Wolff (18). The membrane suspension 
also was sedimented into a pellet with a microfuge running for 5 min. 
The supernatant solution was aspirated from the top and the pellet was 
counted. All three procedures gave identical results, indicating that 
little free colchicine was trapped on the filter papers. 
Disc Gel Electrophoresis-The sodium dodecyl sulfate polyacrylam- 
ide gels were run as described by Weber and Osborn (19) with 
phosphate buffer (pH 7.1). The gel contained 5% acrylamide and 0.2% 
bisacrylamide. In all gels, polymerization was initiated by the addition 
of N,N,N’,N’-tetramethylethylenediamine and ammonium persulfate. 
The samples were run at a current of 4 mA/tube at 23” until the 
tracking dye reached the end of the gel. The gels were stained with 
0.02% Coomassie brilliant blue in 50% methanol and 9% acetic acid 
and destained in 5% methanol and 7.5% acetic acid. 
Protein was determined by the method of Lowry (20) using bovine 
serum albumin as standard. [“C]Leucine-labeled tubulin was pre- 
pared from the soluble fraction of rat brain by the method of Eipper 
(21). The specific activity was 18,000 cpm/mg of protein. 
hadioimmunoassay-Two rabbits were injected at multiple sites 
with 0.5 mg of purified rat brain tubulin (mixed with 4 ml of complete 
Freund’s adjuvant) weekly for 2 weeks, and then at 2.week intervals for 
3 months. The serum was stored at 20”. The titers were assayed by 
radioimmunoassay with ‘251-tubulin as described below. 
Iodination of tubulin was carried out according to a modification of 
the method of Hunter and Greenwood (22) using one-tenth the 
recommended amount of chloramine-T and sodium metabisulfite. The 
labeled ‘2”I-tub;llin was separated from free lzsI on a Sephadex G-75 
column. 
The assay mixture contained: (a) 0.1 ml of diluted antiserum (in 
0.1% albumin and 0.2 M phosphate buffer pH 7.0); (b) 10 ~1 of 
‘2SI-tubulin diluted in albumin buffer in order to give 5000 cpm; and 
(c) 10 ~1 of co!d antigen in the same buffer. Volumes were made up to 
0.5 ml by adding the same albumin buffer. Samples were incubated for 
1 hour at 37” and 12 hours at 4”. Then 0.1 ml of normal rabbit serum 
(diluted 1:lOO) was added to each tube, followed by 0.2 ml of undiluted 
sheep anti-rabbit y-globulin antiserum and the incubation was contin- 
ued for 12 hours at 4’. The tubes were centrifuged for 15 min at 4000 x 
g to separate free and antibody-bound ‘251-tubulin. The supernatant 
fluid was then aspirated and the pellet was counted. Controls used in 
these experiments contained nonimmune serum in place of anti- 
tubulin serum. 
AdenyEate Cyclase-Adenylate cyclase was assayed by the method 
of Salomon et al. (23) using incubation conditions described earlier 
(24). 
Materials 
Preparation of Tritiuted Vinblastine-Raditiactive vinblastme was 
prepared by an exchange method using [3H]trifluoroacetic acid in a 
variation of the method of Owellen and Daring (25). Five milligrams of 
vinblastine sulfate were dissolved in 0.2 ml of trifluoroacetic acid. To 
this were added 25 mg of 5% rhodium on Al,O, as catalyst and 10 Ci of 
tritiated water. After 2 days at room temperature labile tritium was 
removed in uacuo with 0.2 ml of methanol and 2.0 ml of ethanol after 
filtration from the catalyst. The compound was taken to dryness from 
methanol twice more. The yield of crude tritiated products was 108 
mCi. Of this approximately 35 to 40% behaved chromatographically as 
vinblastine. The crude product was repeatedly purified by chromatog- 
raphy on silica plates (Ql-Quantum Industries) in chloroform/ 
methanol (9/l). The final product had a radiochemical purity of 93 to 
95%. Specific activity was not determined but was calculated to be 
>19 mCi/pmol, i.e. sufficiently high not to contribute significant 
amounts of carrier in the present experiments. 
GTP (Grade IIS) was obtained from Sigma. Tritiated colchicine 
(ring C, methowy-3H), a product of New England Nuclear Corp., 
had a specific activity of 2.5 Ci/mmol. Brij 35 SP was purchased from 
Atlas Chemical Industries and Nonidet P-40 was obtained from BDH, 
England. All other detergents were obtained from commercial sources. 
Vinblastine sulfate was a gift from Eli Lilly and Co. The colchicine 
analogues used were gifts of Dr. Colin Chignell. Podophyllotoxin was 
the gift of Dr. W. J. Gensler of Boston University. 
RESULTS 
Membrane Preparation and Distribution of Colchicine-bind- 
ing A&i&y--In rat brain homogenates prepared by the 
method of Gray and Whittaker (15), 50 f  5% of the colchicine- 
binding activity was found in the soluble fraction, while the 
crude nuclear and mitochondrial fractions accounted for 15% 
and 35 f  5%, respectively. When the crude nuclear fraction 
was further purified in 2.4 M sucrose containing 1 M MgCl, at 
50,000 x g for 1 hour, there was almost no activity in pure 
nuclei and more than 90% of the activity was recovered in the 
soluble phase. This suggested that essentially all the binding 
activity of the crude nuclear fraction was due to contamination 
by soluble or weakly bound colchicine-binding protein (Table 
I). On the other hand, the bulk of the activity in mitochondrial 
suspensions disrupted by mild sonication and repeated wash- 
ing was still bound to particles (Table I). 
Further purification of this crude mitochondrial fraction (15) 
did not give a clear-cut enrichment of the colchicine binding in 
one particular fraction. While the brief sonication may have 
removed trapped colchicine-binding activity, it made the 
composition of the synaptosome fraction less specific. Mem- 
branes were, therefore, purified by a different method (14) 
based on enrichment of the F--activated adenylate cyclase in 
the case of brain, and thyrotropin-stimulated adenylate cyclase 
in the case of thyroid. It is clear from Fig. 1 that the fraction 
recovered at the 40% sucrose interface showed the highest 
TABLE I 
Fractionation of colchicine-binding actiuity in brain and thyroid 
Subcellular fractionation was carried out by a slight modification of 
the procedure of Gray and Whittaker (15). The crude mitochondrial 
fraction was briefly sonicated and washed three times with 0.32 M 
sucrose to ensure removal of trapped soluble protein. 
Colchicine-binding 
Tissue fraction activity 
Brain Thyroid 
Nuclei (M,) 
Crude 
Purified 
Washings from crude nuclei 
Mitochondria (M,) 
Crude 
“Myelin” 
“Synaptosomes”” 
Mitochondria 
Soluble cytoplasmic 
% of total homqwate 
15 10 
1 0 
14 10 
30 18 
8 4 
15 9 
7 5 
50-55 70-75 
“This fraction would also contain all those membranes produced by 
sonication. 
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specific activities for colchicine binding. In thyroid membranes 
this coincided with the highest specific activity for adenylate 
cyclase, whereas in brain the enzyme activities were equal at 
the 40% and 45% sucrose interfaces. The fraction at the 40% 
sucrose interface was, therefore, used in subsequent studies. 
In comparison to brain, thyroid is a poor source for colchi- 
tine-binding protein (26). Nevertheless, the amounts present 
readily permitted an estimate of about 18 to 20% of the total 
colchicine-binding activity in this tissue as particle-bound 
(Table I). The distribution of colchicine-binding activity in the 
subcellular fractions was roughly the same as in brain by both 
methods of fractionation (Table I). Enrichment for colchicine- 
binding activity in the same fractions as adenylate cyclase 
suggested that much of this binding protein was in the plasma 
membranes of thyroid and brain. 
Is this colchicine-binding protein of membrane fractions due 
to tubulin tightly linked to the membrane or to nonspecific 
adsorption of soluble tubulin during homogenization? When 
[“Clleucine-labeled tubulin (prepared from rat brain) (21) was 
added before homogenizing the brain, more than 97% of the 
radioactivity appeared in the crude soluble fraction and less 
than 0.1% of the radioactivity was associated with any of the 
fractions after separation by discontinuous sucrose gradient 
centrifugation (Table II). Similar data were obtained using the 
method of Gray and Whittaker (15); no significant amount of 
label was associated with the purified particulate fractions 
(data not shown). It seems unlikely, therefore, that the colchi- 
tine-binding activity of membrane fractions was due to the 
contamination by a soluble tubulin or an artifact of separation. 
Next we attempted to determine whether the colchicine- 
binding activity of particulate fractions was due to tubulin 
present in membranes or to the presence of other colchicine- 
binding proteins. Solubilization of colchicine-binding activity 
was attempted by use of detergents. At the same time, we 
tested how much each detergent affected colchicine binding to 
soluble brain tubulin (Table III). Although sodium dodecyl sul- 
fate and sodium deoxycholate solubilized large portions of the 
membrane protein, these detergents abolished all binding ac- 
tivity even at 0.05%. It was therefore necessary to find a deter- 
gent that did not interfere with colchicine binding to soluble 
tubulin but was still able to solubilize such activity from the 
membranes. Among the detergents tested, the extent of over-all 
solubilization of membrane protein decreased in the order 
Triton X-100 (0.1%) > Lubrol PX (0.1%) > Tween 20 (0.1%) 
> Brij 35 (0.1%) > Tween 40 (0.1%) > Nonidet P-40 (0.1%). 
FIG. 1. Distribution of adenylate cy- 
clase and colchicine-binding activities 
in different sucrose gradient fractions. 
Fluoride (10 mM) was used as stimulant 
for brain, and bovine thyrotropin (TSH) 
(200 milliunits/ml) for thyroid adenylate 
cyclase. For the colchicine-binding as- 
say, the membrane protein concentra- 
tions were 1.3 mg/ml for brain and 1.7 
mg/ml for thyroid tissue. Samples were 
incubated at 37’ for 1.5 hours with 1.0 
x 10m5 M [3H]co1chicine and binding 
activity was measured according to 
Williams and Wolff (17). 
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This was the reverse order of the recovery of colchicine-binding 
activity in the solubilized fraction (Table III). The soluble 
fraction prepared with Nonidet P-40 was highest in relative 
colchicine-binding activity. The proteins solubilized from rat 
brain membranes by sodium dodecyl sulfate and by Nonidet 
P-40 are shown in Fig. 2. It is clear that many fewer bands 
appear in the Nonidet P-40 preparation but also that one of the 
two major bands migrates with the same mobility as purified 
soluble rat brain tubulin. Similar results were obtained with 
detergent extracts from beef thyroid membranes (data not 
shown). 
We therefore chose Nonidet P-40 as the most useful deter- 
gent for the present purposes. Fig. 3 shows the effect of the 
concentration of Nonidet P-40 on the extent of extraction of the 
active colchicine-binding protein from both brain and thyroid 
membranes. Since the presence of 0.2% Nonidet P-40 during 
the long incubation at 37” decreased the extent of colchicine 
binding by the solubilized protein, we precipitated the solubi- 
lized protein with 55% (NH,),SO, after extraction with Noni- 
det P-40. No differences were noted in the extent of solubiliza- 
tion of binding activity from brain and thyroid. 
Affinity for Colchicine-Analysis of tritiated colchicine bind- 
ing to membrane-bound colchicine-binding protein, solubi- 
lized binding protein, and soluble tubulin was performed by 
Lineweaver-Burk plots (Fig. 4). The binding constants for 
membrane-bound and solubilized colchicine-binding protein 
from brain (1.0 x 106, 0.7 x lo6 M-l) are very similar to that 
obtained for soluble brain tubulin (1.4 x lo6 Mm’) (8, 29, 30); 
for thyroid the constant was 0.6 x lo6 Mm’ for both membrane 
and solubilized colchicine-binding activity compared with 
TABLE II 
~istributionofadded ["C]tubulinindifferentsubcellularfractionsof 
rat brain 
[“CJTubulin, 18,000 cpm, was added during the homogenization of 
brain. Fractionation was carried out according to Wolff and Jones (14). 
Tissue fraction 
Homogenate 
Soluble supernatant 
30% 
40% 
45% 
Pellet 
“C 
c/J* 
17,540 
17,100 
15.4 
3.6 
<l.O 
<l.O 
1 THYROID 
q BASAL 
q X~ULATED 
CYCLASE 
COLCHICINE 
BINDING 
4506 PELLET 
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TABLE III 
Solubilization of membrane-bound colchicine-binding protein with various detergents 
Detergents 
Sqdium dodecyl sulfate, 0.05% 
Sodium deoxycholate, 0.05% 
Triton X-100,0.1% 
Lubrol PX, 0.1% 
Tween 20,0.1% 
Brij 35,0.1% 
Tween 40,0.1% 
Nonidet P-40,0.2% 
Per cent Per cent of 
of total protein colchicine-binding 
solubilized activity solubilized 
Brain Thyroid Brain Thyroid 
93.0 53.2 0 0 
64.6 38.4 0 0 
40.4 23.1 7-10 8 
34.8 23.0 9 10 
24.9 21.4 10 11 
21.6 19.4 14 11.5 
18.0 19.0 20 13 
16.4 18.5 80-90 85 
Per cent inhibition of 
colchicine-binding 
activity in tubulin 
Brain Thyroid 
100 100 
100 100 
75 72 
60 64 
53 60 
48 52 
41 50 
0 0 
FIG. 2. Sodium dodecyl sulfate acrylamide disc gel electrophoresis. 
The gels, pictured from left to right, are: 1, protein standards, from top 
to bottom, 19 S and 12 S thyroglobulin, phosphorylase b, transferrin, 
glutamic dehydrogenase, aldolase, carbonic anhydrase, and myo- 
globin; 2, purified rat brain tubulin; 3, Nonidet P-40-treated rat brain 
membrane fraction; and 4, sodium dodecyl sulfate-treated rat brain 
membrane fraction. 
0.5 x lo6 M- ’ for soluble thyroid tubulin (17,26). 
We were also able to compare the colchicine-binding activity 
of both membrane-bound and solubilized colchicine-binding 
protein with that of soluble tubulin using the various analogues 
of colchicine. Analogues like colcemid and colchiceine reduced 
binding of radioactive colchicine by membrane-bound and 
solubilized protein by 55 and 20%, respectively, when present 
in lo-fold excess. These displacements are comparable to those 
observed with soluble tubulin (1, 27). On the other hand, a 
lo-fold excess of colchicoside and isocholchicine did not 
prevent labeled colchicine from binding to soluble tubulin, 
membrane-bound, or solubilized colchicine-binding protein of 
both brain and thyroid preparations. This is in agreement with 
the known effects of these analogues’ (see Ref. 1). 
I Another method of assessing binding of colchicine to tubulin is by 
fluorescence. Although colchicine does not fluoresce significantly in 
IId 
0 0.2 0.4 
NONIDET-P40 IPERCENT) 
FIG. 3. Release of colchicine-binding protein from rat brain 
(O----O) and beef thyroid membranes (A-A) with Nonidet P-40. 
The rat brain membrane (1.5 mg/ml) and beef thyroid membrane (1.8 
m,r$ml) were suspended in various concentrations of Nonidet P-40 at 4’ 
for 30 min and then centrifuged at 37,000 x g for 20 min at 4’. 
Solubilized colchicine-binding protein of the supernatant solution was 
precipitated with 60% ammonium sulfate for 30 min at 4’, and 
centrifuged for 20 min at 37,000 x g. The pellet was resuspended in 
0.25 M sucrose/l0 mM sodium phosphate (pH 7.0)/10 mM MgClJO.1 
mM GTP buffer, and the colchicine-binding activity was measured as 
described. 
Another similarity between the soluble tubulin and the 
colchicine-binding protein present in the membrane is their 
interaction with podophyllotoxin, a known competitive inhibi- 
tor for colchicine binding (28, 29). Podophyllotoxin inhibited 
colchicine binding to membrane proteins and its solubilized 
form with K, values (Fig. 5) similar to those obtained for 
soluble tubulin. In brain these constants were 3.5, 3.8, and 2.0 
x 10-O M respectively, for membrane, solubilized, and soluble 
colchicine-binding activity. For thyroid tissue Ki values were 
1.8, 2.5, and 1.8 x lOMe M, respectively, for membrane, 
solubilized, and soluble colchicine-binding activity. 
Vinblustine Binding-Another alkaloid, vinblastine, binds 
nonpolar solvents, fluorescence of colchicine is promoted upon binding 
to soluble tubulin (29). We were therefore surprised that no fluores- 
cence could be elicited when colchicine was bound to membranes. 
Three possible reasons for this difference are: (a) association with the 
membrane puts constraints on tubulin that permits binding but not the 
promotion of fluorescence. This seems unlikely since affinity constants 
for colchicine in membranes of both thyroid and brain are the same as 
for their soluble counterparts. However, we cannot rule this out until 
the reason for the promotion of fluorescence is better understood. (b) 
The protein in the membrane is different. (c) Some membrane 
component other than the bound tubulin quenches the fluorescence. 
This appears, at present, the most likely explanation since fluorescence 
of colchicine in the presence of soluble tubulin is abolished by addition 
of membranes (unpublished results). 
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tubulin, but at a site different from the colchicine-binding 
site (28, 30). Table IV shows the distribution of vinblastine- 
binding activity in different membrane fractions for both rat 
brain and beef thyroid tissue. Like the colchicine-binding 
activity, vinblastine-binding activity is highest in the mem- 
brane fraction at the 40% sucrose interface. But unlike the 
colchicine-binding activity, there is also very high vinblastine- 
binding activity in the fraction at the 45% sucrose interface. In 
the thyroid, the pellet also contained a substantial amount of 
binding activity. It seems probable from these results, as well as 
the fact that vinblastine is a cation at neutral pH, that 
vinblastine binding is less specific than colchicine binding. 
Nevertheless, it appeared to be useful to compare binding 
constants for vinblastine in membrane, solublized, and soluble 
protein preparations from brain and thyroid. The association 
constants for tritiated vinblastine to membranes, solubilized 
protein, and soluble tubulin were determined by Lineweaver 
Burk plots as shown in Fig. 6. The association constants 
obtained were -8 x lo6 Mm’ for all preparations and are very 
similar to that obtained by Owellen et al. for pig brain tubulin 
(30). 
Stability-A characteristic of the colchicine-binding site of 
the tubulin is its lability at 37” (28). In the presence of 
vinblastine and sucrose, this labile colchicine-binding site can 
be protected (28, 31). Fig. 7 shows the decay characteristics of 
colchicine binding at 37”. In contrast to soluble tubulin (Curve 
4), membrane-bound colchicine-binding protein from both 
,- 
,- 
BRAIN 
4 
THYROID 
/I 
0 
;r-; 
0 A 
/ 
FIG. 4. Lineweaver-Burk plots of the binding of [aH]colchicine to 
tubulin. For brain the protein concentrations were 200 fig, 1.05 mg, 
and 220 rg/ml for soluble (A-A), membrane-bound (O--El), and 
solubilized (O--O) colchicine-binding protein, respectively. For 
thyroid these values were 240 rg, 1.31 mg, and 248 rg/ml for solu- 
ble, membrane-bound, and solubilized protein, respectively. Samples 
were incubated at 37” for 1.5 hours. 
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brain and thyroid was relatively stable at 37’ (Curve 3). Decay 
of colchicine-binding capacity also was diminished by vinblas- 
tine and sucrose (Curves 2 and I). When the colchicine-binding 
protein was solubilized from the membrane, it decayed at the 
same rate as did soluble tubulin (Curue 5). Thus, the environ- 
ment of the membrane may play the same role that sucrose and 
vinblastine do for protecting the binding site against decay at 
37”. This increased stability also indicates that there is fairly 
tight binding between membrane and colchicine-binding pro- 
tein rather than simple physical trapping. In contrast, tubulin 
entrapped in chick brain synaptic vesicles exhibits normal 
decay rates for colchicine-binding activity (32). 
Temperature Optimum for Colchicine Binding-Colchicine- 
binding activity in tubulin from brain or thyroid tissue is 
strongly influenced by temperature. There is no binding at 0” 
(17, 28, 29); binding is maximal at 37” and equilibration is 
slow. Above 37”, binding falls off sharply. In contrast to soluble 
tubulin, membrane-bound tubulin from both brain and thy- 
roid shows an optimum temperature for colchicine binding at 
54” for both brain and thyroid membranes (Fig. 8). When 
membrane-bound protein was solubilized, it showed the same 
-10.0 -5.0 0 5.0 10.0 -5.0 0 5.0 10.0 
POOOPHYLLOTOXIN tpM) 
FIG. 5. Modified Dixon plot demonstrating the effect of podophyl- 
lotoxin on the colchicine-binding reaction. The concentration of 
podophyllotoxin present is plotted against the reciprocal of bound 
colchicine at several concentrations of colchicine: 04, 1.0 PM; 
A-A, 2.2 FM; 04, 3.5 pM. The protein concentrations were 1.1 
mg and 242 rg/ml for particulate and solubilized protein in the case of 
brain and 1.31 mg and 252 pg/ml for thyroid. All samples were in 0.25 M 
sucrose/l0 mM sodium phosphate (pH 7.0)/10 mM MgClJ0.1 mM GTP 
buffer, incubated at 37” for 1.5 hours. 
TABLE IV 
Distribution of uinblastine-binding actiuity in different tissue fractions 
Aliquots of each tissue fraction for both brain and thyroid were 
incubated with 1 x lo-” M [SH]vinblastine for 1 hour at 37” and the 
bound vinblastine was determined by filter disc method as used in case 
of colchicine-binding (17). Protein concentrations are 500 rg/ml in all 
fractions for brain and 250 fig/ml for each fraction in thyroid. 
Tissue fraction at interface 
Specific activity 
Brain Thyroid 
Sucrose 
30% 
40% 
45% 
Pellet 
2.2 5.4 
17.4 26.1 
13.8 22.1 
2.0 a.3 
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-1 
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BRAIN 0 
- t 
THYROID 
FIG. 6. Lineweaver-Burk plots of the binding of ]3H]vinblastine to 
tubulin. In brain the protein concentrations were 200 pg, 1.05 mg, and 
220 pg/ml for soluble (A-A), membrane-bound (O--O), and 
solubilized (04) tubulin. For thyroid these values were 210, 200, 
and 248 Kg/ml in case of soluble, membrane-bound, and solubilized 
tubulin. Samples were incubated at 37” for 1 hour and bound 
vinblastine was determined by the same filter disc method as used in 
the case of colchicine binding (17). 
temperature optimum for colchicine binding (37”) as does 
soluble tubulin. Fig. 8 also shows that the temperature 
optimum for soluble tubulin changes to higher temperatures in 
the presence of stabilizing agents such as sucrose and vin- 
blastine. This close parallelism between the sucrose and vin- 
blastine effects on the one hand, and membrane binding on 
the other, with respect to the temperature optimum for 
colchicine binding, suggests that the colchicine-binding site 
is similarly protected in all cases. 
Tub&in Antibodies-An additional method for comparing 
soluble and membrane-bound tubulin was provided by use of 
antibodies directed against soluble rat brain tubulin. Although 
antiserum titers were relatively low, they permitted identifica- 
tion of cross reactivity of membrane-bound and solubilized 
material with soluble brain tubulin. 
To determine the optimal dilution of antiserum for the 
radioimmunoassay, the “‘I-tubulin bound to antibody at 
various dilutions of antiserum was measured (Fig. 9). A 
dilution of l/10 precipitated about 50 to 60% of the labeled 
tubulin. Only 8% of the label was precipitated in this double 
antibody technique when nonimmune serum was used, and 5% 
when buffer alone was used. Using this dilution of antiserum, 
various amounts of unlabeled tubulin were added to the assay 
mixture, and free and bound radioactivity were determined. 
Unlabeled tubulin competed with the iodinated tubulin and 
prevented the latter from binding to antibody (Fig. 10). Mem- 
brane-bound colchicine-binding protein and the solubilized 
protein from brain and thyroid membranes displaced label in 
the same fashion as did the soluble tubulin. It is interesting 
that anti-brain tubulin antibody binds to membrane-bound 
colchicine-binding protein from both brain and thyroid, show- 
ing that there is little species or tissue specificity, in agreement 
with earlier studies (33, 34). 
TIME (HOURS1 
FIG. 7. Loss of [3H]colchicine binding of soluble tubulin, mem- 
brane-bound, and solubilized colchicine-binding protein from rat brain 
and beef thyroid membranes as a function of incubation time at 37” 
and conditions of incubation. Conditions for both brain and thyroid 
are: Curve 1 (A-A), soluble tubulin in 10 mM sodium phosphate 
(pH 7.0)/10 mM M&1,/0.1 mM GTP solution (PMG buffer) containing 
1 M sucrose; &rue 2 (O--O), soluble tubulin in PMG buffer contain- 
ing 1 x lo-’ M vinblastine; Curve 3 (O----O), membrane-bound colchi- 
tine-binding protein in PMG buffer; Curve 4 (.A), soluble tubulin 
in PMG buffer; and Curve 5 (A-A), solubilized colchicine-binding 
protein in PMG buffer. Protein concentrations are: 240 pg/ml for 
Curves 1, 2, and 4 in the case of brain and 262 &ml in thyroid; Curue 
3, 1.1 mg/ml for brain and 1.25 mg/ml for thyroid; Curve 5, 205 fig/ml 
for brain and 282 rig/ml for thyroid. Samples were preincubated at 37” 
and the colchicine-binding activity was measured for 1.5 hour at 37’ at 
the end of the preincubation period. 
DISCUSSION 
In the present study we report the presence of substantial 
amounts of particulate colchicine-binding activity in brain and 
thyroid tissue. Brain contains about twice the proportion of the 
total activity in the particulate form as thyroid. These find- 
ings on brain are in general agreement with earlier reports 
(10, 12, 28, 35, 36). The subcellular distribution of colchicine- 
binding activity has revealed the highest binding to be 
associated with the synaptosome fraction, which, in our 
procedure, would also contain membranes derived by sonica- 
tion (10, 12, 37). An additional site for colchicine binding has 
been found in the nuclear membrane of liver cells and Lilium 
meiocytes (13, 38, 39). However, in contrast to soluble tubulin, 
the liver membrane binds lumicolchicine as well as colchicine. 
It seems probable that such binding is nonspecific since 
lumicolchicine binding in brain was not displaced by colchi- 
tine or podophyllotoxin and was not temperature-dependent 
(32). In the present study, direct isolation of membranes has 
shown that enrichment for adenylate cyclase is accompanied 
by enrichment in colchicine-binding activity. This suggests 
that the plasma membrane is a major contributor to particu- 
late colchicine binding (Table I, Fig. 1). 
Characterization of the membrane-bound colchicine-binding 
activity can be accomplished by detailed kinetic and analogue 
studies of colchicine binding, by various forms of chemical 
characterization of protein extracted from membranes, or by 
immunological techniques. To our knowledge, the present 
report is the first where all of the approaches have been 
combined, thus leading to considerably greater confidence in 
the identification of the membrane-bound colchicine-binding 
activity. 
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5 / THYROID 1- I 
TEMPERATURE loci 
FIG. 8. Determination of the optimum temperature for colchicine 
binding in different incubation conditions. Incubation conditions for 
both thyroid and brain are: Curue I (.A), soluble tubulin in 10 
mM sodium phosphate (pH 7.0)/10 mM MgClJU.1 mM GTP solution 
(PMG buffer); Curue 2 (04). membrane-bound colchicine-binding 
protein in PMG buffer; Curue 3 (A-A), soluble tubulin in PMG 
buffer containing 1 x lo-’ M vinblastine; Curue 4 (m-m), soluble 
tubulin in PMG buffer containing 1 M sucrose; and Curve 5 (O-O), 
solubilized colchicine-binding protein in PMG buffer. Protein con- 
centrations are: Curve 1, 280 pg/ml; Curve 2, 700 pg/ml; Curve 3, 180 
fig/ml; Curve 4, 253 fig/ml; and Curoe 5, 193 pg/ml for brain tissue. 
For thyroid these values are: Curve 1, 1.4 mg/ml; Curve 2, 2.8 mg/ml; 
Curve 3, 1.20 mg/ml; Curve 4, 1.20 mg/ml; and Curve 5, 480 &ml. 
Samples were incubated at the designated temperatures for 1.5 hours. 
LOG DILUTION OF ANTISERUM 
FIG. 9. Standard curve for the antigen-antibody reaction between 
‘ZSI-tubulin and antitubulin antiserum. The per cent of ‘2SI-tubulin 
bound to antibody is plotted against the log of the dilution of 
antiserum in the assay mixture. ‘2SI-tubulin (approximately 5000 cpm 
in 10 ~1) was incubated with 0.1 ml of several dilutions of antiserum. 
After 1 hour at 37’ and 12 hours at 4”, 0.1 ml of a 1:lOO dilution of 
normal rabbit serum was added, followed immediately by 0.2 ml of 
undiluted sheep anti-rabbit y-globulin. After 1‘2 hours further incuba- 
tion at 4”, free and antibody-bound ‘*51-tubulin were separated by 
centrifugation and counted. 
Affinity constants for the binding of colchicine, vinblastine, 
or podophyllotoxin (as K,) to membranes have not, heretofore, 
been measured. As shown in Figs. 4 to 6, the affinity was the 
same for soluble tubulin, purified membranes, and binding 
protein solublized from such membranes. This was true for 
both rat brain and beef thyroid tissue. Analogues of colchicine 
acted equally on colchicine-binding protein from all three 
sources. Thus colcemid and colchiceine showed activity 
against colchicine binding by membranes, whereas colchicoside 
and isocolchicine were inactive, as is the case with soluble 
tubulin (27, 29). For both brain and thyroid tissue, podophyllo- 
I BRAIN 
I 1 1 1 
THYROID 
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FIG. 10. Displacement of ‘251-tubulin from antibody by unlabeled 
colchicine-binding protein. The radioimmunoassay was performed 
using an antiserum dilution of 1:lOO. A 10.~1 aliquot of soluble tubulin 
(O--O), membrane-bound (A-A), and solubilized (0-O) 
colchicine-binding protein was added to the reaction mixture as in Fig. 
9. Note that for soluble brain tubulin only, a different range of con- 
centration is shown above the abscissa. 
binding activity. Bamburg et al. (32) also have shown that 
podophyllotoxin inhibits binding of colchicine by chick brain 
particulate fractions. Finally, while vinblastine appears to be a 
less specific agent for tubulin than colchicine (40), it is never- 
theless a useful adjunct in the identification of tubulin-like 
proteins. Affinity for vinblastine was the same for soluble, 
membrane, and solubilized protein. On the basis of binding 
criteria, therefore, the colchicine-binding activity of brain or 
thyroid membranes. and the solubilized protein derived from 
these membranes, resemble soluble tubulin in every respect so 
far examined. 
The chemical characterization of membrane colchicine- 
binding activity has frequently required extraction procedures 
that destroyed binding activity. Thus Feit et al. (37) showed 
that membranes contained a protein of the same electro- 
phoretic mobility (in polyacrylamide gels) as soluble tubulin. 
This protein also shows considerable similarity in peptide 
maps, although not all peptides of pure tubulin were demon- 
strated in membrane-derived material (41). Following the 
procedure of Hotta and Shepard (39) we were able to treat 
brain and thyroid membranes with detergents that extracted 
only a few proteins. Among these was nearly all of the 
colchicine-binding activity. One of the major protein bands of 
this extract showed a molecular weight of 55,000 in disc gel 
electrophoresis, i.e. like the subunit molecular weight of 
soluble tubulin from these tissues (Fig. 2). While it is not yet 
possible to show coincidence of this protein band with the 
colchicine-binding activity of the extracts, the appearance of 
both of these properties of tubulin in the membrane extract 
supports the suggestion that the binding activity of the mem- 
branes is, in fact, tubulin. 
Additional evidence for the tubulin-like nature of the mem- 
brane-bound colchicine-binding activity was provided by im- 
munologic means. It had been shown previously that brain 
particulates showed the best complement fixation reaction 
with antibodies against soluble tubulin (42). As shown in the 
present study (Figs. 9 and lo), both brain and thyroid 
membranes, and the solubilized colchicine-binding activity, 
precipitated with anti-brain tubulin in a double antibody 
toxin yielded K, values that did not vary with the source of the technique. This again suggests the considerable similarity 
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between soluble and membrane colchicine-binding activity. 
Certain apparent differences have been observed between 
the behavior of membrane and soluble tubulin that merit 
attention. Thus membrane tubulin is far more stable than 
soluble tubulin and exhibits a colchicine-binding optimum 
near 54”. That this probably results from the bound state and 
the resultant change in the environment of the protein is 
demonstrated by two observations. (a) When tubulin is ex- 
tracted from either brain or thyroid membranes its stability 
characteristics revert to that of soluble tubulin. (b) If  soluble 
tubulin is kept in 1.0 M sucrose or vinblastine, its stability is 
very near that of membrane tubulin. We believe, on the basis 
of this evidence, that the stability difference is not an intrinsic 
property of the protein in the membrane but rather of its 
environment. The change in thermal stability of membrane 
tubulin also argues against simple entrapment of cytoplasmic 
tubulin inside membrane vesicles. Therefore, on the basis of 
binding, chemical, and immunological properties, we conclude 
that the colchicinelbinding activity of membranes is very 
similar to, if not identical with, soluble tublulin. 
An important consequence of the membrane locus for 
tubulin is that while colchicine effects on various cellular 
processes, such as secretion (l), may be specific for tubulin, 
they are not necessarily specific for microtubules. Since such 
secretory processes as endo- and exocytosis intimately involve 
membranes, the interpretation of colchicine effects as operat- 
ing through the participation of microtubules cannot be made 
unambiguously, even when the structure of microtubules is 
seen to be altered. Similar considerations apply to the effects of 
colchicine on the mobility of membrane surface constituents 
(43, 44) and they may be pertinent to the effects of this drug 
on transport processes (45). By what means colchicine binding 
to membrane tubulin may alter the function of such mem- 
branes remains to be determined. 
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